{"preliminary_commentary":{"by_channel":{"youtube":2,"x_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"TATIN","nct_id":"NCT04148066","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=tatin-nct04148066. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"TATIN","arms":[{"description":"Osimertinib will be administered according to label: 80 mg once daily.\n\nCrizotinib will only be prescribed upon detection of MET amplification using ctDNA. Crizotinib will be administered according to label: 250 mg bi-daily.","label":"Osimertinib and Crizotinib","type":"OTHER"}],"collaborators":["Roche Pharma AG"],"completion_date":{"date":"2021-12-17","type":"ACTUAL"},"conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":{"count":104,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"ctDNA blood sample","otherNames":[],"type":"DIAGNOSTIC_TEST"}],"last_update":"2023-10-10","lead_sponsor":"The Netherlands Cancer Institute","official_title":"Track and Treat in NSCLC (TATIN) - ctDNA Guided Treatment of Early Resistance to Targeted Treatment in Patients With EGFR Positive NSCLC","overall_status":"COMPLETED","phases":["NA"],"primary_completion_date":{"date":"2021-12-17","type":"ACTUAL"},"primary_outcomes":[{"measure":"percentage of patients in which a drug resistant clone can be detected with ctDNA","timeFrame":"Trough study completion, an average of 2 years"}],"references":[],"start_date":{"date":"2019-07-17","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"ctDNA Guided Treatment of Early Resistance to Targeted Treatment","url":"https://clinicaltrials.gov/study/NCT04148066"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/tatin-nct04148066"}